Sickle Cell Disorders clinical trials at UC Health
1 research study open to new patients
A Study of the Safety Of Experimental Medicine Rivipansel (GMI-1070) For Hospitalized Patients With Sickle Cell Disease
open to eligible people ages 6 years and up
This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).
at UC Davis